Biomedical subjects
O K Linde
Publications and source records attributed to O K Linde.
Coffee and tea influence pharmacokinetics of antipsychotic drugs.
Explore the source record for details and available documents.
Clinical trial of droperidol for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured using Haase's graphopathological test) and the maximum dose were determined. The neuroleptic threshold dose was 18.5 mg/day (SD = 8.84), the maximum dose was 38.2 mg/day (SD = 4.6). With reference to the effectiveness good to very good results were obtained in 15 cases. Regarding side effects 10 patients complained of extrapyramidal disturbances. This was to be expected in view of the study design aiming at the determination of the maximum dose.
Precipitation of antipsychotic drugs in interaction with coffee or tea.
Explore the source record for details and available documents.
[Incidence of anonymous medication before admission to the hospital (author's transl)].
Only about 1/4 of the statements made by the patients or accompanying persons regarding preclinical medication proved to be true. In about 66% of the cases 1--5 drugs were not stated during the first interview, while in 10% of the cases more drugs were stated than had actually been taken. Among the substances which had remained anonymous, the main shares are represented by benzodiazepines (28%), narcotic drugs (19%), neuroleptics (15%) and alcohol (15%). If one relates the number of false statements to the individual patients grouped according to diagnoses, the relatively highest quota of defaulters is found among the addicts, namely, 100%. This means that all the addicts had made false statements. The second rank is occupied by the alcoholic group who made 66% false statements, followed by the patients suffering from psychoses with 52% false statement, and the depressive patients with 47% false statements.
Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured via Haase's graphopathological test), the maximum dose, and the maintenance dose were determined. The neuroleptic threshold dose was 5.6 mg/day (0.08 mg/kg body weight); the maximum dose was 11 mg/day (0.16 mg/kg body weight); and the maintenance dose was 6 mg/day (0.09 mg/kg body weight). With reference to the effectiveness, good to very good results were obtained in 19 cases. Regarding side effects 15 patients complained of extrapyramidal disturbances, this was to be expected in view of the study design aiming at the determination of the maximum dose level. When administered in one single dose in the evening, bromperidol influenced the night sleep positively, so that sleep-inducing drugs could be reduced, and, in some cases, even dispensed with.
[Neuroleptic potency of bromperidol].
Explore the source record for details and available documents.
[Problem-free air purification in clinics and offices].
Explore the source record for details and available documents.
Neuroleptic potency of bromperidol.
The following statements can be made on the basis of our study. 1. The butyrophenone bromperidol is an absolutely effective drug of the series of very high-potency neuroleptics, with a mean neuroleptic threshold dose of 5.6 mg/day. The mean optimum dose is 6 mg/day, and the mean maximum dose reaches 11 mg/day, i.e. twice the neuroleptic threshold dose. 2. The substance is generally well tolerated; when it was administered to one third of all cases in one single dose in the evening, it not only had the same beneficial neuroleptic-antipsychotic effect as on administration t.i.d., but also positively influenced sleep, so that sleep-inducing drugs could be reduced and, in some cases, even dispensed with. This relatively long-lasting effect confirms the finding made in animal experiments.